- Home
- EXK vs SLS Comparison
EXK vs SLS Comparison
Compare EXK & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXK | SLS |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EXK | SLS |
|---|---|---|
| Price | $8.23 | $9.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $15.50 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 6.2M | 4.5M |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $90.95 | N/A |
| Revenue Next Year | $33.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.60 | $1.39 |
| 52 Week High | $15.15 | $15.88 |
Technical Indicators
Market Signals| Indicator | EXK | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 34.96 |
| Support Level | $7.33 | $9.19 |
| Resistance Level | $8.83 | $12.53 |
| Average True Range (ATR) | 0.32 | 0.73 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 41.51 | 4.91 |
Price Performance
Historical ComparisonAbout EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has three operating mining segments namely; Guanacevi and Terronera in Mexico, and Minera Kolpa in Peru. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.